CH644762A5 - Arzneimittel zur behandlung von zu erhoehtem fibrinogengehalt im blutplasma fuehrenden pathologischen prozessen. - Google Patents

Arzneimittel zur behandlung von zu erhoehtem fibrinogengehalt im blutplasma fuehrenden pathologischen prozessen. Download PDF

Info

Publication number
CH644762A5
CH644762A5 CH538478A CH538478A CH644762A5 CH 644762 A5 CH644762 A5 CH 644762A5 CH 538478 A CH538478 A CH 538478A CH 538478 A CH538478 A CH 538478A CH 644762 A5 CH644762 A5 CH 644762A5
Authority
CH
Switzerland
Prior art keywords
fibrinogen
plasma
carrageenan
injection
injected
Prior art date
Application number
CH538478A
Other languages
German (de)
English (en)
Inventor
Gerhard Prof Ruhenstroth-Bauer
Reiner Dr Scherer
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19772722769 external-priority patent/DE2722769C3/de
Priority claimed from DE2750920A external-priority patent/DE2750920C3/de
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Publication of CH644762A5 publication Critical patent/CH644762A5/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CH538478A 1977-05-20 1978-05-18 Arzneimittel zur behandlung von zu erhoehtem fibrinogengehalt im blutplasma fuehrenden pathologischen prozessen. CH644762A5 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19772722769 DE2722769C3 (de) 1977-05-20 1977-05-20 Verwendung von Fibrinogen
DE2750920A DE2750920C3 (de) 1977-11-15 1977-11-15 Verwendung von Fibrinopeptiden A und B

Publications (1)

Publication Number Publication Date
CH644762A5 true CH644762A5 (de) 1984-08-31

Family

ID=25772044

Family Applications (1)

Application Number Title Priority Date Filing Date
CH538478A CH644762A5 (de) 1977-05-20 1978-05-18 Arzneimittel zur behandlung von zu erhoehtem fibrinogengehalt im blutplasma fuehrenden pathologischen prozessen.

Country Status (4)

Country Link
US (1) US4215109A (enExample)
JP (1) JPS5417107A (enExample)
CH (1) CH644762A5 (enExample)
GB (1) GB1603244A (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5104639A (en) * 1980-01-14 1992-04-14 Esa, Inc. Method for biological testing and/or developing pharmaceuticals for treatment of disorders using electrochromatography
US6333160B1 (en) 1988-08-31 2001-12-25 Keiji Tamura Method and specific diagnostic system for objectively assessing and monitoring the relative homeostasis and health of animals
ES2114654T3 (es) * 1993-06-08 1998-06-01 Vertex Pharma Piridazinas como inhibidores de la enzima de conversion de la interleuquina-1beta.
US7605132B2 (en) * 2001-08-29 2009-10-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Protective factors against inflammation, burns and noxious stimuli
US7528227B2 (en) * 2004-03-23 2009-05-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Histone H2A peptide derivatives and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3973001A (en) * 1954-04-27 1976-08-03 Solco Basel Ag Tissue cell stimulating blood extracts
US2847348A (en) * 1954-05-27 1958-08-12 Ortho Pharma Corp Plasma fractionation and product therefrom
US2847349A (en) * 1954-05-27 1958-08-12 Ortho Pharma Corp Plasma preparation
US3466368A (en) * 1967-06-02 1969-09-09 Us Health Education & Welfare Cleavage of human gamma globulin by means of cyanogen bromide
AT275038B (de) * 1967-11-15 1969-10-10 Immuno Ag Verfahren zur Gewinnung von reinem Blutalbumin aus Hämopigmente enthaltenden Proteinlösungen
US3916026A (en) * 1968-09-19 1975-10-28 Biotest Serum Institut Gmbh Method for the preparation of gamma-globulin suitable for intravenous use
US3717708A (en) * 1968-10-24 1973-02-20 Cutter Lab Blood coagulation complex
US3664994A (en) * 1969-06-30 1972-05-23 Upjohn Co Process for separating horse gamma globulin fractions by chromatography
US3763135A (en) * 1971-11-08 1973-10-02 Baxter Laboratories Inc Gamma globulin production from cohn fraction iii using polyethylene glycol
US4073886A (en) * 1973-01-30 1978-02-14 Baxter Travenol Laboratories, Inc. Blood fractionation process using block copolymers of ethylene oxide and polyoxypropylene
US3808189A (en) * 1973-03-15 1974-04-30 American Cyanamid Co Isolation of gamma globulin preparations enriched in iga and igm using polyethylene glycol
US3893990A (en) * 1973-04-05 1975-07-08 Baxter Laboratories Inc Clarification of blood serum and plasma using a block copolymer of ethylene oxide and polyoxypropylene
US3893991A (en) * 1973-04-05 1975-07-08 Baxter Laboratories Inc Clarification of blood serum and plasma using block copolymers of ethylene oxide and polyoxypropylene
US3973002A (en) * 1974-04-12 1976-08-03 E. R. Squibb & Sons, Inc. Antihemophilic factor
JPS5176418A (en) * 1974-12-26 1976-07-02 Teijin Ltd Menekiguroburinno seizoho
DE2500076C3 (de) * 1975-01-02 1982-11-18 SCHURA Blutderivate GmbH & Co KG, 4150 Krefeld Verfahren zur Gewinnung von intravenös-verträglichen Gammaglobulinen
CA1064396A (en) * 1975-02-18 1979-10-16 Myer L. Coval Fractional precipitation of gamma globulin with polyethylene glycol
US4087415A (en) * 1976-06-09 1978-05-02 William L. Wilson Antithrombin III
US4081432A (en) * 1977-07-25 1978-03-28 Monsanto Company Method of separating a Factor IX preparation from plasma using ethylene-maleic anhydride polymers

Also Published As

Publication number Publication date
US4215109A (en) 1980-07-29
JPS5417107A (en) 1979-02-08
GB1603244A (en) 1981-11-18
JPS6341890B2 (enExample) 1988-08-19

Similar Documents

Publication Publication Date Title
DE69130289T2 (de) Therapeutische verwendung von actin-bindenden verbindungen
DE69123960T2 (de) Behandlung von entzündungen
EP0233279B1 (de) Neuartige verwendung von taurolin
DD288094A5 (de) Verwendung von gamma-interferon zur behandlung von gefaessverengungen
DE3937607A1 (de) Verwendung eines antikoagulanz zur behandlung von tumorerkrankungen
EP0004668B1 (de) Faktor zur Stimulation der Proliferationsrate von Leberzellen und diesen Faktor als Wirkstoff enthaltende Arzneimittel
DE2715832B2 (de) Verfahren zur Gewinnung von gereinigtem antihämophilem Globulin A (Faktor VIII)
CH644762A5 (de) Arzneimittel zur behandlung von zu erhoehtem fibrinogengehalt im blutplasma fuehrenden pathologischen prozessen.
EP0017867B1 (de) Arzneimittel zur Stimulation der Proliferation von Leberzellen und Leberschutz- und Wachstumsfaktor
Fruhman Adrenal steroids and neutrophil mobilization
DE2835292C2 (de) Verfahren zur Herstellung von entfibrinisierten und gefriergetrockneten Placentazellen
DE3306944C2 (enExample)
DE69607417T2 (de) Verwendung von Batroxobin enthaltende Arzneimittel zur Behandlung und Prophylaxe von ischämischen Reperfusionsschäden
DE2750920C3 (de) Verwendung von Fibrinopeptiden A und B
DE2715748B2 (de) Gereinigte aktive Verbindung des Plasminogen-Typs menschlichen Ursprungs und ihre Verwendung
DE3612232A1 (de) Verwendung von menschlichem urogastron zur foerderung der heilung von knochen und/oder sehnen
EP0401347B1 (de) Verwendung von transferrin zur bekämpfung der toxischen wirkung des endotoxins bei der endotoxinämie
DE1802386C2 (de) Verfahren zur Gewinnung von cytobiotischen Globulinen
DE2722769C3 (de) Verwendung von Fibrinogen
EP0255651A2 (de) Mittel zur Therapie faktor VIII-resistenter Hämophilie A und Verfahren zu seiner Herstellung
EP0864092B1 (de) Komplex-gebundene hemmstoffe aktivierbarer stoffwechselenzyme als molekulare marker zur diagnostik und therapieüberwachung
DE3250068C2 (enExample)
EP0005243A2 (de) Kontrollplasma, dessen Herstellung, dessen Verwendung zur Ueberwachung der oralen Antikoagulantientherapie sowie Reagenziengarnitur enthaltend dieses Kontrollplasma
EP0189485A1 (de) Hexapeptid
CH525251A (de) Verfahren zur Herstellung einer therapeutisch aktiven Aspergillopeptidase zur Verhinderung der Bildung von Blutgerinnseln

Legal Events

Date Code Title Description
PL Patent ceased
PL Patent ceased